## Clinical Presentation Analysis This patient has **localized cutaneous lichen planus** (dorsal hands and wrists only) with: - Non-erosive papules - Mild pruritus - Confirmed histology - No oral involvement - Negative hepatitis C and normal LFTs **Key Point:** The absence of erosive oral disease, limited body surface area involvement, and mild symptoms classify this as **localized, non-severe cutaneous LP** — the most common presentation. ## Treatment Ladder for Cutaneous Lichen Planus | Severity | First-Line | Second-Line | Third-Line | |---|---|---|---| | **Localized (< 10% BSA), non-erosive** | Topical corticosteroids ± occlusion | Intralesional corticosteroids | Topical calcineurin inhibitors | | **Generalized (> 10% BSA), non-erosive** | Topical corticosteroids + systemic retinoids | Systemic corticosteroids | Azathioprine, cyclosporine | | **Erosive (oral or cutaneous)** | Systemic corticosteroids | Systemic retinoids, azathioprine | Cyclosporine | ## Why Topical Corticosteroids with Occlusion 1. **First-line for localized cutaneous LP**: Topical corticosteroids are the standard initial therapy for non-erosive, localized disease. 2. **Clobetasol propionate 0.05%** is a potent (Class I) topical corticosteroid appropriate for: - Hands and wrists (thicker skin, lower absorption risk) - Papular lesions with good penetration - Mild-to-moderate pruritus 3. **Occlusion enhances efficacy**: Plastic wrap or occlusive dressing increases drug penetration and is standard practice for localized LP on extremities. 4. **Twice-daily dosing** is typical for potent topical steroids in localized disease; duration is usually 2–4 weeks with reassessment. **High-Yield:** **Localized cutaneous LP = topical corticosteroids ± occlusion** is the gold standard. Systemic therapy is reserved for generalized or erosive disease. ## Why Other Options Are Not Appropriate **Intralesional triamcinolone** (Option A): - Used for **resistant localized lesions** or as adjunctive therapy - Not first-line; topical therapy should be tried first - More invasive and time-consuming for multiple papules - Appropriate if topical therapy fails after 4–6 weeks **Oral acitretin** (Option B): - Reserved for **generalized cutaneous LP** or erosive disease - Not indicated for localized, mild, non-erosive papules - Teratogenic; requires strict contraception in women of childbearing age - Slower onset (weeks to months) compared to topical corticosteroids **Systemic corticosteroids** (Option D): - Indicated for **erosive oral LP** or **generalized, severe cutaneous LP** - Not justified for localized, mild, non-erosive disease - Higher risk of adverse effects (immunosuppression, HPA axis suppression, metabolic effects) - Disproportionate risk-benefit ratio for this presentation ## Clinical Pearl **Warning:** Do not over-treat localized lichen planus. Many cases of localized cutaneous LP resolve spontaneously over months to years. Topical corticosteroids provide symptomatic relief and accelerate resolution without systemic toxicity. ## Management Flowchart ```mermaid flowchart TD A[Lichen Planus confirmed]:::outcome --> B{Erosive involvement?}:::decision B -->|Yes| C[Systemic corticosteroids]:::action B -->|No| D{Localized cutaneous<br/>< 10% BSA?}:::decision D -->|Yes| E[Topical corticosteroids<br/>± occlusion]:::action D -->|No| F{Generalized cutaneous<br/>or refractory?}:::decision F -->|Yes| G[Systemic retinoids<br/>or corticosteroids]:::action E --> H[Reassess at 4 weeks]:::action H -->|Improved| I[Continue, taper]:::action H -->|Resistant| J[Add intralesional<br/>or topical tacrolimus]:::action ``` 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.